Beyond KRAS: Practical Molecular Targets in Pancreatic Adenocarcinoma

Pancreatic adenocarcinoma (PDAC) has a grim prognosis. Molecular and genomic analyses revealed that the striking majority of these tumors are driven by KRAS mutation, currently not amenable to targeted therapy. However, other driver mutations were found in a small fraction of patients. Herein we rep...

Descripción completa

Detalles Bibliográficos
Autores principales: Grinshpun, Albert, Zarbiv, Yonaton, Roszik, Jason, Subbiah, Vivek, Hubert, Ayala
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381925/
https://www.ncbi.nlm.nih.gov/pubmed/30792639
http://dx.doi.org/10.1159/000496018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381925/
https://www.ncbi.nlm.nih.gov/pubmed/30792639
http://dx.doi.org/10.1159/000496018

Ejemplares similares